Company
Team
CORPORATE GOVERNANCE
Platforms
Glycovirology
Degenerative Diseases
pipeline
ProLectin Pipeline
Degenerative Disease pipeline
Resources
IN THE NEWS
Stroke video
faq
SCIENTIFIC PUBLICATIONS
investors
Company presentation
press releases
Reports
financial
Contact US
$BIXT
Company
Platforms
Glycovirology
Degenerative Diseases
Resources
Investors
Pipeline
contact us
Glycovirology Scientific Publications
featured
Galectin approach to lower covid transmission - Drug Development for clinical use
Galectin approach to lower covid transmission - Drug Development for clinical use
Chemokines modulate glycan binding and the immunoregulatory activity of galectins
Chemokines modulate glycan binding and the immunoregulatory activity of galectins
An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial
An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial
load more
Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studies
Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studies
Immunopathology of galectin-3: an increasingly promising target in COVID-19
Immunopathology of galectin-3: an increasingly promising target in COVID-19
A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure
Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure
Previous
load more
go back